Stifel 2026 Healthcare Conference 2026
Logotype for Olema Oncology Inc

Olema Oncology (OLMA) Stifel 2026 Healthcare Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Olema Oncology Inc

Stifel 2026 Healthcare Conference 2026 summary

11 Nov, 2026

OPERA clinical programs

  • OPERA-01, a 2L/3L monotherapy study, is expected to read out in Q1; the key test is whether phase II results replicate in phase III. Phase II median PFS was 7.3 months in ESR1-mutant and 5.5 months in wild-type patients.

  • Palazestrant’s proposed differentiators include a 14-day half-life, higher exposure and complete ER antagonism; OPERA-01 separately analyzes ESR1-mutant and wild-type populations.

  • OPERA-02, a first-line study with KISQALI, is enrolling robustly. Enrollment excludes endocrine-resistant patients with less than 6 months’ response to prior endocrine therapy in advanced disease.

  • OPERA-02 enrollment may be expanded after review of SERENA-4 control-arm data at San Antonio in early December; added enrollment would modestly extend timing, while readout depends on event rate.

Combination data and pipeline

  • San Antonio presentations will include mature post-CDK4/6 everolimus-combination data with Kaplan-Meier PFS, tolerability and ESR1-mutant/wild-type analyses.

  • Atirmociclib combination enrollment is complete; initial tolerability and response-rate data will be presented in a mixed frontline/post-CDK4/6 population, without mature durability data.

  • The KAT6 inhibitor poster will update monotherapy and show initial breast-cancer fulvestrant-combination tolerability across multiple dose levels; dose selection remains ongoing.

  • Palazestrant plus KAT6 data are targeted for mid-2027; prostate-cancer enrollment with NUBEQA is expected to start in the near future, with data earliest by late 2027.

Commercial strategy and financing

  • Success in both OPERA-01 populations could support an oral endocrine option across a broader market; management cited a ~$5B opportunity, including $3B with no competition, versus ~$2B for ESR1-mutant disease.

  • U.S. launch preparations are underway, with a potential launch around mid-2028 contingent on a positive, fileable OPERA-01 readout; plans include U.S. and ex-U.S. filings and seeking collaborators for launch and ex-U.S. markets.

  • Cash was $414M at Q3 end, expected to support the launch window conditional on OPERA-01; management cited a favorable cash position and potential non-equity capital options.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Olema Oncology